Endotoxin Testing for Antibody-Drug Conjugates (ADCs): Managing Complex Matrices, Recovery, and Method Suitability

Introduction

Antibody-drug conjugates (ADCs) represent one of the most sophisticated classes of modern biopharmaceutical products. By combining a monoclonal antibody or antibody fragment with a chemical linker and a potent small-molecule payload, ADCs are designed to deliver therapeutic activity to specific target cells while limiting exposure to non-target tissues.

This multi-component structure creates unique analytical and manufacturing challenges.

The antibody component behaves like a biologic. The linker and payload may introduce chemical and physicochemical characteristics that are very different from conventional protein therapeutics. Formulations may also contain surfactants, stabilizers, sugars, salts, buffers, and other excipients.

For endotoxin testing, this complexity matters.

A bacterial endotoxin test is not simply a matter of adding an ADC sample to a TAL/LAL Reagent and reading the result. The sample matrix can affect endotoxin availability, assay kinetics, spike recovery, and the apparent concentration reported by the test.

FDA describes ADCs as products containing multiple constituent parts, including an antibody or antibody fragment, a chemical linker, and a small-molecule drug or payload. The agency issued specific guidance for ADC development in 2024, reflecting the distinctive analytical and development considerations associated with these products.

For laboratories developing or testing ADCs, the central question is therefore not simply:

“Can endotoxin be detected?”

It is:

“Can endotoxin be measured reliably in this specific ADC matrix under the selected test conditions?”

This article explains the major endotoxin testing challenges associated with ADCs and outlines a practical strategy for sample preparation, method suitability, dilution, recovery, and quantitative testing.

For a broader introduction to sample preparation, dilution, matrix interference, and recovery, see FireGene's Endotoxin Testing Sample Preparation: A Practical Guide to Dilution, Interference, Recovery, and Reliable Results.

1. Why Endotoxin Testing Is Particularly Important for ADCs

Bacterial endotoxins are lipopolysaccharide-associated components originating primarily from the outer membrane of Gram-negative bacteria.

They can enter pharmaceutical manufacturing systems through:

• Process water
• Raw materials
• Buffers
• Manufacturing equipment
• Single-use components
• Filtration systems
• Containers and closures
• Handling and environmental contamination

Endotoxins are also different from viable microorganisms.

A process may successfully remove or destroy bacteria while leaving biologically active endotoxin behind. FDA notes that endotoxin control therefore requires attention to potential sources throughout manufacturing rather than relying solely on final-product testing.

For ADC manufacturing, this becomes particularly important because the product passes through multiple processing stages.

A simplified ADC manufacturing workflow may include:

Antibody Production → Purification → Linker/Payload Preparation → Conjugation → Purification → Formulation → Sterile Filtration → Filling

Each stage introduces different potential endotoxin risks.

The endotoxin control strategy should therefore be considered across the manufacturing lifecycle rather than only at the final product stage.

2. Why ADCs Are More Complex Than Conventional Protein Samples

A conventional recombinant protein formulation may already present challenges for endotoxin testing.

An ADC can be more complicated because it combines several chemically and biologically distinct components.

An ADC formulation may contain:

• Monoclonal antibody
• Linker
• Cytotoxic payload
• Residual process components
• Surfactants
• Stabilizers
• Sugars
• Amino acids
• Salts
• Buffer components
• Other formulation excipients

The physicochemical properties of these components can influence the behavior of endotoxin in the sample.

For example, endotoxin may interact with proteins, hydrophobic components, surfactants, or other formulation ingredients. These interactions may alter how much endotoxin is available to participate in the assay reaction.

This means that a method that works well for a simple aqueous sample may not automatically perform the same way when applied to an ADC formulation.

That distinction is fundamental to successful endotoxin testing.

For additional discussion of how proteins, surfactants, concentrated solutions, and other complex materials can influence endotoxin recovery, see FireGene's Endotoxin Testing Sample Preparation guide and Endotoxin Testing for Raw Materials and Excipients.

3. Potential Sources of Endotoxin During ADC Manufacturing

Endotoxin contamination can originate from multiple stages of ADC production.

Antibody Production

If the antibody is produced using a biological expression system, endotoxin control must begin well before the final ADC is assembled.

Raw materials, process water, equipment, and purification systems can all contribute to endotoxin risk.

Biologically derived materials require particularly careful control because endotoxin may become associated with proteins or process intermediates.

For a broader discussion of controlling endotoxin before manufacturing begins, see FireGene's Endotoxin Testing for Raw Materials and Excipients: A Complete Guide for Pharmaceutical QC.

Purification

Downstream purification is expected to reduce process-related impurities, but endotoxin removal should not be assumed automatically.

Changes in chromatography conditions, buffer preparation, filtration, or equipment cleaning can influence endotoxin levels.

Testing selected intermediates can help identify whether endotoxin is being effectively controlled or removed during downstream processing.

Conjugation

The conjugation step introduces another layer of complexity.

The chemical environment may change significantly during linker and payload attachment. Solvents, pH changes, reaction conditions, purification reagents, and other process components can affect the final matrix.

Even if the conjugation reaction itself is not a direct source of endotoxin, changes in the process can influence how endotoxin behaves during subsequent analytical testing.

Formulation

The final formulation may contain surfactants, stabilizers, salts, sugars, or other components designed to maintain ADC stability.

These ingredients can influence endotoxin detection.

This is particularly important when apparent endotoxin recovery changes over time.

Sterile Filtration and Filling

Sterile filtration and aseptic filling represent additional control points.

Filtration does not automatically eliminate endotoxin, and endotoxin can be introduced from components, equipment, water, or handling.

For this reason, endotoxin control should be integrated with broader process controls rather than treated as an isolated laboratory activity.

4. The Biggest Analytical Challenge: Matrix Interference

One of the most important concepts in ADC endotoxin testing is matrix interference.

A sample matrix can interfere with endotoxin detection in several ways.

Inhibition

Inhibition occurs when sample components reduce the response generated by the endotoxin assay.

The result may be an apparent endotoxin concentration that is lower than the actual concentration.

For an ADC, potential contributors can include:

• High protein concentration
• Surfactants
• Certain buffers
• Chelating agents
• Extreme pH
• High ionic strength
• Other formulation components

Enhancement

Enhancement represents the opposite problem.

The sample produces a stronger assay response than expected, potentially resulting in an apparent endotoxin concentration higher than the true value.

Both inhibition and enhancement can undermine quantitative endotoxin testing.

This is why method suitability is more important than simply selecting a highly sensitive reagent.

FireGene's How to Validate an Endotoxin Test Method: A Step-by-Step Guide for USP <85> Compliance provides additional discussion of inhibition, enhancement, MVD, PPC recovery, and method suitability for complex pharmaceutical matrices.

5. Why Positive Product Controls Matter

A Positive Product Control (PPC) is an important tool for evaluating whether the sample matrix is interfering with the endotoxin assay.

The basic concept is straightforward:

Sample + Known Endotoxin Spike → Measured Recovery

The measured response is compared with the expected response from the known endotoxin addition.

If the recovery is acceptable, the selected sample condition provides evidence that the matrix is not causing unacceptable inhibition or enhancement under the test conditions.

If recovery is poor, the laboratory may need to investigate:

• Sample dilution
• pH
• Sample preparation
• Formulation effects
• Reagent compatibility
• Endotoxin masking
• Sample storage conditions

For ADCs, PPC evaluation should be treated as a meaningful part of method development rather than simply a box to check.

FireGene's Endotoxin Recovery Studies Explained: How to Design, Perform, and Interpret Recovery Experiments provides a more detailed discussion of spike recovery and why recovery studies evaluate the analytical system in the presence of the actual product matrix.

6. Endotoxin Recovery Can Change Over Time

One of the more subtle problems associated with complex biologic formulations is Low Endotoxin Recovery (LER).

LER occurs when an endotoxin spike that initially demonstrates acceptable recovery becomes increasingly difficult to recover after the sample has been stored or incubated under certain conditions.

This can create a particularly challenging situation:

The assay appears valid, but the endotoxin becomes progressively less detectable in the product matrix.

FireGene's detailed Understanding Low Endotoxin Recovery (LER): Mechanisms, Regulatory Perspectives, and Practical Solutions in 2026 discusses endotoxin masking, time-dependent recovery, and the analytical challenges associated with complex biologic formulations.

This is especially relevant when an ADC contains components capable of interacting with endotoxin.

A practical investigation may therefore compare:

Day 0 → Day 1 → Day 3 → Day 7

or another scientifically justified time sequence.

The objective is to determine whether endotoxin recovery remains stable over the intended sample handling and storage period.

LER should not automatically be interpreted as proof that endotoxin has been eliminated.

Instead, the laboratory should consider whether the endotoxin has become less accessible to the detection system.

For a more detailed distinction between ordinary product inhibition and LER, FireGene's How to Validate an Endotoxin Test Method also discusses why dilution may improve ordinary inhibition but may not resolve time-dependent endotoxin masking.

7. Choosing the Appropriate Dilution

Dilution is one of the most practical tools available for controlling matrix interference.

The challenge is finding a dilution that provides sufficient matrix relief without reducing the endotoxin concentration below the useful analytical range.

The basic relationship can be expressed as:

Analytical Sensitivity + Matrix Compatibility + Acceptable Recovery = Suitable Test Dilution

Too little dilution may leave the sample matrix highly inhibitory or enhancing.

Too much dilution may reduce the endotoxin concentration to a level that is difficult to quantify reliably.

For applicable bacterial endotoxin testing strategies, the Maximum Valid Dilution (MVD) also needs to be considered.

MVD represents the maximum permissible dilution based on the product endotoxin limit and assay sensitivity.

A practical development sequence may therefore look like:

Undiluted Sample → Initial Dilution Series → PPC Evaluation → Recovery Assessment → Optimized Dilution → Confirmatory Testing

The goal is not necessarily to choose the lowest possible dilution.

The goal is to identify a scientifically justified condition that provides acceptable recovery and reliable endotoxin measurement.

FireGene's Endotoxin Testing Sample Preparation guide provides additional guidance on dilution, MVD, pH, storage, matrix interference, and recovery.

For laboratories establishing endotoxin limits and calculating MVD, FireGene's How to Set Endotoxin Limits for Pharmaceutical Products can be used as a complementary resource.

8. Selecting a TAL/LAL Reagent for ADC Testing

The choice of endotoxin test method should be based on the intended application, sample characteristics, sensitivity requirements, and validated method.

Gel-Clot Endotoxin Testing

Gel-clot testing remains useful when a qualitative or semi-quantitative endpoint is appropriate.

FireGene's Gel-Clot LAL/TAL Endotoxin Test Kit is available in multiple sensitivity levels, including 0.03, 0.06, 0.125, 0.25, and 0.5 EU/mL. The product page specifies a 37°C reaction environment and a typical test time of approximately 60 minutes.

For laboratories working with ADC-related research samples, a gel-clot assay can provide a relatively straightforward approach when the sample matrix is compatible with the method.

However, complex ADC formulations may benefit from quantitative analysis during method development.

Kinetic Chromogenic Endotoxin Testing

Kinetic chromogenic testing measures the development of a chromogenic signal over time and converts the kinetic response into quantitative endotoxin information.

FireGene's Kinetic Chromogenic Endotoxin Test Kit is a 96-well quantitative TAL/LAL assay with a listed detection range of 0.005–10 EU/mL and 405 nm absorbance detection. The product is identified by FireGene as Research Use Only and is not licensed by FDA for end-product release of FDA-regulated pharmaceutical drugs, devices, or biologics.

For ADC method development, a quantitative workflow can be particularly useful because it allows laboratories to compare:

• Different sample dilutions
• Different formulation conditions
• Different recovery experiments
• Different manufacturing intermediates
• Different sample hold times
• Different reagent lots
• Historical endotoxin trends

Quantitative data can provide more information than a simple positive/negative endpoint.

For additional background on kinetic chromogenic assay principles, standard curves, PPCs, and data interpretation, see FireGene's The Ultimate Guide to Kinetic Chromogenic Endotoxin Assays.

9. A Practical ADC Endotoxin Testing Workflow

A robust ADC endotoxin testing strategy can be organized into several stages.

Step 1: Characterize the Sample

Before testing, document the formulation.

Consider:

• ADC concentration
• pH
• Buffer composition
• Surfactants
• Stabilizers
• Salt concentration
• Sample appearance
• Expected endotoxin limit
• Intended administration route

This information helps identify potential interference mechanisms.

Step 2: Establish an Initial Dilution Range

Do not immediately assume that the undiluted sample is the best testing condition.

Prepare an appropriate dilution series based on the expected endotoxin concentration and applicable MVD.

Step 3: Evaluate PPC Recovery

Spike a known endotoxin concentration into the selected sample dilution.

Compare the observed recovery with the expected response.

Step 4: Investigate Inhibition or Enhancement

If recovery is unacceptable, investigate the sample matrix.

Possible strategies include:

• Increasing dilution
• Adjusting sample preparation
• Evaluating another compatible test condition
• Investigating formulation components
• Assessing sample storage effects

Step 5: Evaluate Time-Dependent Recovery

For complex ADC formulations, consider whether endotoxin recovery changes after defined sample hold periods.

This step can be particularly informative when surfactants or other components may interact with endotoxin.

Step 6: Confirm the Selected Method

Once a suitable testing condition has been identified, confirm the method's performance under the intended conditions of use.

The resulting procedure should be reproducible and appropriate for the specific ADC matrix.

For a detailed step-by-step framework covering endotoxin limits, MVD, PPC recovery, inhibition/enhancement, and method suitability, see FireGene's How to Validate an Endotoxin Test Method.

10. Common ADC Endotoxin Testing Mistakes

Mistake 1: Treating an ADC Like a Simple Protein

An ADC contains multiple structural and formulation components.

Assuming that a method validated for a conventional protein will automatically work for an ADC can create analytical risk.

Mistake 2: Testing Only the Final Product

Final-product testing is important, but it may not identify where endotoxin entered the process.

Testing selected raw materials, buffers, process intermediates, and manufacturing inputs can provide additional information about process control.

Mistake 3: Using Excessive Dilution

More dilution does not automatically mean better endotoxin testing.

If the sample is diluted beyond the scientifically justified range, a low result may simply reflect inadequate analytical sensitivity.

Mistake 4: Ignoring Time-Dependent Recovery

A PPC that passes immediately after sample preparation does not necessarily prove that endotoxin recovery will remain stable during a prolonged hold.

Complex ADC formulations may require additional evaluation.

Mistake 5: Focusing Only on the Reagent

An endotoxin assay is a complete analytical system.

Reliable results depend on:

Reagent + CSE + Assay Water + Consumables + Sample Preparation + Dilution + Temperature + Timing + Instrument + Data Analysis

FireGene's Control Standard Endotoxin (CSE), Endotoxin Assay Water, and Pyrogen-Free Vials can be incorporated into appropriate endotoxin-testing workflows to help control these analytical variables.

11. Building a Risk-Based ADC Endotoxin Control Strategy

A modern ADC endotoxin strategy should connect manufacturing controls with analytical testing.

A useful framework is:

Raw Materials

↓

Process Water and Buffers

↓

Antibody Production

↓

Purification

↓

Conjugation

↓

Downstream Processing

↓

Formulation

↓

Sterile Filtration

↓

Filling

↓

Final Product Testing

At each stage, the laboratory and manufacturing teams should ask:

1. What is the potential source of endotoxin?
2. How could endotoxin enter the process?
3. Can endotoxin be removed at this stage?
4. Could the matrix interfere with detection?
5. What sample dilution is appropriate?
6. Is PPC recovery acceptable?
7. Could endotoxin recovery change over time?
8. What historical trend should be monitored?

This approach transforms endotoxin testing from an isolated laboratory test into a broader contamination-control strategy.

For laboratories deciding where and when to collect samples across a manufacturing process, FireGene's How to Build an Endotoxin Testing Sampling Plan: Where, When, and How Often Should You Test? provides a complementary framework for risk-based sampling.

FDA's March 2026 guidance continues to recognize gel-clot, photometric, and kinetic approaches and emphasizes that appropriate components and finished products should be evaluated for endotoxins and pyrogens according to the applicable testing framework.

At the same time, FDA has also clarified its current thinking around recombinant-reagent approaches and USP <86>, emphasizing that laboratories should verify that a selected method is suitable for its intended use and the specific material being tested.

That principle is particularly relevant to complex products such as ADCs.

12. How FireGene Endotoxin Testing Solutions Can Support ADC Method Development

For laboratories developing endotoxin testing workflows for complex biologic samples, FireGene provides multiple TAL/LAL-based endotoxin testing components.

The Kinetic Chromogenic Endotoxin Test Kit provides a quantitative microplate-based workflow with 405 nm detection and a listed 0.005–10 EU/mL range. Its quantitative format can be useful for research and method-development studies involving dilution, recovery, and matrix evaluation.

For simpler qualitative or semi-quantitative applications, the Gel-Clot Endotoxin Test Kit provides multiple sensitivity options from 0.03 to 0.5 EU/mL.

Supporting materials such as Control Standard Endotoxin, Endotoxin Assay Water, and Pyrogen-Free Vials can also be incorporated into a controlled endotoxin-testing workflow.

For laboratories looking for a broader portfolio of endotoxin-testing reagents and consumables, FireGene's Endotoxin Assay Reagents and Kits collection brings these testing components together in one place.

The key is not simply choosing a sensitive reagent.

The objective is to build a complete analytical system in which:

Sample Preparation → Dilution → PPC Recovery → Method Suitability → Quantitative or Qualitative Testing → Data Interpretation

are connected and scientifically justified.

Conclusion

Endotoxin testing for antibody-drug conjugates presents challenges that go beyond conventional protein analysis.

The combination of antibody, linker, payload, and formulation components creates a complex matrix that may influence endotoxin availability and assay performance.

For ADC laboratories, the most important considerations include:

• Identifying potential endotoxin sources throughout manufacturing
• Understanding ADC-specific matrix effects
• Selecting an appropriate TAL/LAL Reagent
• Establishing a suitable dilution strategy
• Evaluating PPC recovery
• Investigating inhibition and enhancement
• Monitoring potential low endotoxin recovery
• Evaluating time-dependent endotoxin recovery when appropriate
• Using quantitative data to support method development
• Connecting analytical testing with broader process controls

The most reliable ADC endotoxin testing strategy is therefore not simply the most sensitive assay.

It is the method that has demonstrated suitability for the actual ADC matrix under the intended conditions of use.

As ADC development continues to expand, laboratories will increasingly need endotoxin methods that can handle complex formulations while providing reproducible, interpretable, and scientifically defensible results.

For research and analytical development teams, combining appropriate sample preparation with well-controlled TAL/LAL endotoxin testing can provide a stronger foundation for understanding endotoxin risk throughout the ADC development process.